Gofen & Glossberg LLC IL Has $17.99 Million Holdings in Allergan PLC. (AGN)
Gofen & Glossberg LLC IL raised its stake in Allergan PLC. (NYSE:AGN) by 5.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 87,764 shares of the company’s stock after purchasing an additional 4,729 shares during the period. Gofen & Glossberg LLC IL’s holdings in Allergan were worth $17,987,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds also recently bought and sold shares of AGN. Gibraltar Capital Management Inc. increased its holdings in shares of Allergan by 3.4% in the 2nd quarter. Gibraltar Capital Management Inc. now owns 27,056 shares of the company’s stock valued at $6,577,000 after acquiring an additional 891 shares during the last quarter. Atria Investments LLC grew its stake in Allergan by 5.2% during the 2nd quarter. Atria Investments LLC now owns 7,690 shares of the company’s stock worth $1,869,000 after buying an additional 380 shares during the last quarter. Gillespie Robinson & Grimm Inc. grew its stake in Allergan by 11.9% during the 2nd quarter. Gillespie Robinson & Grimm Inc. now owns 109,683 shares of the company’s stock worth $26,663,000 after buying an additional 11,666 shares during the last quarter. Iberiabank Corp grew its stake in Allergan by 4.8% during the 2nd quarter. Iberiabank Corp now owns 5,449 shares of the company’s stock worth $1,325,000 after buying an additional 249 shares during the last quarter. Finally, Addison Capital Co grew its stake in Allergan by 3.1% during the 2nd quarter. Addison Capital Co now owns 10,561 shares of the company’s stock worth $2,567,000 after buying an additional 319 shares during the last quarter. 81.34% of the stock is currently owned by institutional investors.
A number of research firms recently issued reports on AGN. Wells Fargo & Company restated an “outperform” rating on shares of Allergan in a research note on Monday, September 11th. Deutsche Bank restated a “buy” rating and set a $262.00 price target on shares of Allergan in a research note on Tuesday, September 12th. BidaskClub downgraded Allergan from a “hold” rating to a “sell” rating in a research note on Thursday, August 17th. Cantor Fitzgerald restated a “hold” rating on shares of Allergan in a research note on Tuesday, August 29th. Finally, Cowen reiterated an “outperform” rating and issued a $400.00 target price on shares of Allergan in a research note on Tuesday, August 29th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $235.25.
Allergan PLC. (NYSE AGN) opened at $169.24 on Thursday. The stock has a market capitalization of $57,161.05, a price-to-earnings ratio of 11.15, a P/E/G ratio of 1.15 and a beta of 1.11. Allergan PLC. has a 1-year low of $160.07 and a 1-year high of $256.80. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.40.
Allergan (NYSE:AGN) last issued its quarterly earnings data on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.06 by $0.09. The firm had revenue of $4.03 billion during the quarter, compared to analysts’ expectations of $4.04 billion. Allergan had a positive return on equity of 8.00% and a negative net margin of 47.27%. Allergan’s revenue was up 11.4% on a year-over-year basis. During the same period in the previous year, the firm posted $3.32 earnings per share. analysts predict that Allergan PLC. will post 16.27 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Friday, November 17th will be issued a dividend of $0.70 per share. The ex-dividend date of this dividend is Thursday, November 16th. This represents a $2.80 annualized dividend and a yield of 1.65%. Allergan’s dividend payout ratio is presently -12.44%.
Allergan announced that its Board of Directors has approved a share buyback plan on Monday, September 25th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the company to buy up to 2.8% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s leadership believes its shares are undervalued.
In other news, insider William Meury sold 11,807 shares of the business’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $173.89, for a total value of $2,053,119.23. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Chris W. Bodine purchased 3,030 shares of the business’s stock in a transaction dated Thursday, December 7th. The stock was bought at an average cost of $164.77 per share, with a total value of $499,253.10. The disclosure for this purchase can be found here. Over the last three months, insiders bought 17,630 shares of company stock valued at $2,890,057. Insiders own 0.36% of the company’s stock.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with Analyst Ratings Network's FREE daily email newsletter.